1. Home
  2. ERAS vs TG Comparison

ERAS vs TG Comparison

Compare ERAS & TG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • TG
  • Stock Information
  • Founded
  • ERAS 2018
  • TG 1988
  • Country
  • ERAS United States
  • TG United States
  • Employees
  • ERAS N/A
  • TG N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • TG Metal Fabrications
  • Sector
  • ERAS Health Care
  • TG Industrials
  • Exchange
  • ERAS Nasdaq
  • TG Nasdaq
  • Market Cap
  • ERAS 348.4M
  • TG 301.0M
  • IPO Year
  • ERAS 2021
  • TG 1989
  • Fundamental
  • Price
  • ERAS $1.37
  • TG $8.58
  • Analyst Decision
  • ERAS Strong Buy
  • TG
  • Analyst Count
  • ERAS 6
  • TG 0
  • Target Price
  • ERAS $4.83
  • TG N/A
  • AVG Volume (30 Days)
  • ERAS 1.7M
  • TG 55.1K
  • Earning Date
  • ERAS 08-11-2025
  • TG 08-06-2025
  • Dividend Yield
  • ERAS N/A
  • TG N/A
  • EPS Growth
  • ERAS N/A
  • TG N/A
  • EPS
  • ERAS N/A
  • TG N/A
  • Revenue
  • ERAS N/A
  • TG $617,839,000.00
  • Revenue This Year
  • ERAS N/A
  • TG N/A
  • Revenue Next Year
  • ERAS N/A
  • TG N/A
  • P/E Ratio
  • ERAS N/A
  • TG N/A
  • Revenue Growth
  • ERAS N/A
  • TG 17.42
  • 52 Week Low
  • ERAS $1.01
  • TG $4.31
  • 52 Week High
  • ERAS $3.45
  • TG $9.22
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 46.81
  • TG 54.15
  • Support Level
  • ERAS $1.31
  • TG $8.45
  • Resistance Level
  • ERAS $1.59
  • TG $8.90
  • Average True Range (ATR)
  • ERAS 0.13
  • TG 0.21
  • MACD
  • ERAS -0.02
  • TG -0.03
  • Stochastic Oscillator
  • ERAS 25.00
  • TG 44.17

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About TG Tredegar Corporation

Tredegar Corp, through its subsidiaries, engages in the manufacture of polyethylene plastic films, polyester films, and aluminum extrusions. Polyethylene plastic films produce plastic films, elastics, and laminate materials that are used in personal care products, surface protection films, and specialty and optical lighting applications. The company operates through segments including PE films, flexible packaging films, and aluminum extrusions. Aluminum extrusions generate the majority of revenue and provide high-quality, soft-alloy, medium-strength aluminum utilized in the building and construction, automotive, consumer durables, machinery and equipment, electrical, and distribution markets. Revenue is generated from the United States, Asia, and Brazil.

Share on Social Networks: